Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Jul 17, 2023
Date Accepted: Oct 6, 2023

The final, peer-reviewed published version of this preprint can be found here:

Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study

Chen H, Hao J, Hu J, Song C, Zhou Y, Li M, Chen J, Liu X, Wang D, Xu X, Xin P, Zhang J, Liao L, Feng Y, Li D, Pan s, Shao Y, Ruan Y, Xing H

Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study

JMIR Public Health Surveill 2023;9:e50894

DOI: 10.2196/50894

PMID: 37976080

PMCID: 10692882

Pretreatment HIV Drug Resistance and the Molecular Transmission Network among HIV-positive Individuals in China in 2022: a Multicenter Observational Study

  • Hongli Chen; 
  • Jingjing Hao; 
  • Jing Hu; 
  • Chang Song; 
  • Yesheng Zhou; 
  • Miaomiao Li; 
  • Jin Chen; 
  • Xiu Liu; 
  • Dong Wang; 
  • Xiaoshan Xu; 
  • Peixian Xin; 
  • Jiaxian Zhang; 
  • Lingjie Liao; 
  • Yi Feng; 
  • Dan Li; 
  • stephen.w Pan; 
  • Yiming Shao; 
  • Yuhua Ruan; 
  • Hui Xing

ABSTRACT

Background:

Emerging HIV drug resistance caused by increased usage of ARV could jeopardize the success of standardized HIV management protocols in resource-limited settings.

Objective:

We characterized PDR among HIV-positive individuals and risk factors in China in 2022.

Methods:

This cross-sectional study was conducted using two-stage systematic sampling according to the WHO’s surveillance guidelines in eight provincial-level administrative divisions in 2022. Demographic information and plasma samples were obtained from study participants. PDR and molecular transmission networks were analyzed using partial pol region sequences in the Stanford HIV drug resistance database and HIV-TRACE, respectively. Logistic regression was used to identify and estimate factors associated with PDR.

Results:

PDR testing was conducted on 2568 participants in 2022. 34.8% (893/2568) were aged 30-49, 81.4% (2091/2568) were male and 3.2% (81/2568) had prior ARV exposure. The prevalence of PDR was 7.4% in reverse RT/PR regions; the prevalence of PDR to NNRTIs, NRTIs, and PIs were 6.3% (163/2568), 1.2% (32/2568) and 0.2% (5/2568), respectively. Prevalence of NNRTIs-related DR was 6.1% (157/2568) for EFV and 6.3% (163/2568) for NVP. The prevalence of PDR was 11.4% and the prevalence of PDR to NNRTIs was 10.3% in Yunnan. Multivariable logistic regression models indicated that PDR was significantly associated with prior ARV exposure (OR: 7.45, 95% CI: 4.50-12.34) and HIV subtype was CRF55_01B (OR: 2.61, 95% CI: 1.41-4.83). Among 618 (24.2%) sequences (nodes) associated with 253 molecular transmission clusters (size range: 2-13), The percentage of individuals without PDR strains and with PDR strains belonging to a cluster were 20.0% (38/190) and 24.5% (580/2365) (P>0.05). CRF07_BC 46.6% (288/618) was the predominant subtype among the sequences in the molecular transmission network.

Conclusions:

The overall prevalence of PDR in China in 2022 was modest. Targeted genotypic PDR testing and medication compliance interventions must be urgently expanded to address PDR among newly diagnosed people living with HIV in China.


 Citation

Please cite as:

Chen H, Hao J, Hu J, Song C, Zhou Y, Li M, Chen J, Liu X, Wang D, Xu X, Xin P, Zhang J, Liao L, Feng Y, Li D, Pan s, Shao Y, Ruan Y, Xing H

Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study

JMIR Public Health Surveill 2023;9:e50894

DOI: 10.2196/50894

PMID: 37976080

PMCID: 10692882

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.